Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micrologix biotech -- Ignore unavailable to you. Want to Upgrade?

To: Larry G. who wrote (666)	2/16/2000 9:15:00 PM
From: Sean Janzen	Read Replies (1) \| Respond to of 792

I was doing a little research to see if MBI 853NL might be a candidate for fast track approval. It appears some drug developers are attempting to receive fast track approval for their S. Aureus medication. The following comes from Raging Bull. Nabi staph vaccine Boca Raton, Florida-based Nabi (NABI) has developed a vaccine designed to protect people from staph infection, a serious complication for some hospital patients. Nabi was looking to reduce the number of infections by 60%, and it has seen positive data towards achieving that goal. Staphylococcus aureus accounts for about 15% of 2 million hospital-related infections recorded in the United States each year. The vaccine, which is currently in Phase III trials, would be a welcome addition to the current stable of antibiotics. Is it really that effective? We will know for sure in about a year. If the data supports moving ahead, Nabi could apply for approval as soon as the fourth quarter of 2000. And if the FDA places the review on fast track because of the urgency of the need, a decision could come within six months.